ipilimumab
Selected indexed studies
- Improved survival with ipilimumab in patients with metastatic melanoma. (N Engl J Med, 2010) [PMID:20525992]
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (N Engl J Med, 2019) [PMID:31562797]
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (N Engl J Med, 2017) [PMID:28889792]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Improved survival with ipilimumab in patients with metastatic melanoma. (2010) pubmed
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) pubmed
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2017) pubmed
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. (2018) pubmed
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial. (2022) pubmed
- Ipilimumab: an investigational immunotherapy for glioblastoma. (2020) pubmed
- Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. (2021) pubmed
- Ipilimumab in prostate cancer. (2013) pubmed
- Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. (2018) pubmed
- Ipilimumab-induced toxicities and the gastroenterologist. (2015) pubmed